BridgeBio Pharma (BBIO)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from BBIO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from BridgeBio Pharma's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $70M | $78M | $9M | $222M | $502M |
| Net income | -$563M | -$481M | -$643M | -$536M | -$725M |
| Free cash flow | -$511M | -$424M | -$529M | -$522M | -$447M |
| EPS (diluted) | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 |
| Operating margin | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% |
Where the revenue comes from
Revenue by products, fiscal 2025.
Superinvestors who own BBIO
From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Tom Steyer Farallon Capital Management LLC |
Added | $800M | 3.7% | Q2 2026 |
| Andreas Halvorsen Viking Global Investors |
Trimmed | $741M | 2.1% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Added | $76M | 0.04% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | $74M | 0.06% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $12M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by BridgeBio Pharma's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 19, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $70.17 | — |
| Mar 19, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $70.17 | — |
| Mar 18, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $70.12 | — |
| Mar 18, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $70.12 | — |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $64.53 | — |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $64.53 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when BBIO trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are BridgeBio Pharma insiders buying the stock?
6 open-market insider purchases of BBIO in the last 12 months, from SEC Form 4 filings.
Which superinvestors own BridgeBio Pharma?
5 of the superinvestors Investingly tracks hold BBIO in their latest 13F, including Tom Steyer, Andreas Halvorsen, PRIMECAP Management.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.